ClearTrial Releases ClearTrial 4
ClearTrial today launched ClearTrial 4, a major upgrade to the company's product line. ClearTrial 4 includes new features that enhance the way that biopharmaceutical and medical device companies plan, source, and track clinical trials. The new release includes ClearTrial Task Manager, a feature which enables organizations to add their own tasks and algorithms extending the ClearTrial Work Breakdown Structure (WBS) to more precisely align with their study requirements and business processes.
ClearTrial Task Manager takes advantage of the software's activity-based costing methodology, which is widely used in industries that have long faced cost and resource pressure. Sometimes referred to as a bottom-up or project-management approach, activity-based costing begins by predicting the level of effort for a specific resource (person) to perform a given task (activity). The level of effort is calculated based on an algorithm that has been derived from experience and analysis of the cost and time drivers that affect each task.
ClearTrial algorithms are based on continuously updated research into clinical study cost and time drivers. Based on this research, all the tasks and subtasks that comprise a clinical study are defined and grouped in a way that helps organize and define the total work scope of the project—the ClearTrial Work Breakdown Structure. Transparent to users, it is this Work Breakdown Structure running in the background that allows ClearTrial customers to conduct accurate study planning by entering their clinical assumptions into the software.
ClearTrial Task Manager provides a view of the tasks and subtasks comprising their current Work Breakdown Structure. Taking a "wizard"-style approach, ClearTrial Task Manager allows users to add, delete, or edit tasks—as well as their related resources and level-of-effort algorithms—with a few clicks of a mouse. For example, a drop-down menu lists more than 20 drivers, such as site, location, or CRF pages that can be used to drive costs for a clinical study task.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
